A rapid high-pressure liquid chromatographic procedure for determination of flumazenil in plasma

被引:6
作者
Zedkova, L [1 ]
Rauw, GA
Baker, GB
Coupland, NJ
机构
[1] Univ Alberta, Dept Psychiat, Psychopharmacol Res Unit, Edmonton, AB T6G 2B7, Canada
[2] Univ Alberta, Neurochem Res Unit, Edmonton, AB T6G 2B7, Canada
基金
加拿大健康研究院;
关键词
methods; flumazenil; high-performance liquid chromatography; panic disorder;
D O I
10.1016/S1056-8719(01)00162-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Flumazenil antagonizes the effects of benzodiazepines at gamma-aminobutyric acid (GABA) type A receptors in the central nervous system. Flumazenil has been reported to provoke panic attacks in patients with panic disorder (PD) but not in healthy controls. A rapid high-pressure liquid chromatographic (HPLC) method was developed for determination of flumazenil in plasma samples from PD patients receiving flumazenil and the results obtained with that assay are reported here. Methods: Samples from 37 PD subjects receiving 2 mg of flumazenil intravenously were analyzed. Extraction under basic conditions was followed by an HPLC assay with UV detection (250 run). Lamotrigine was used as internal standard and a standard curve was constructed for each assay run. Flumazenil concentrations were measured in all the subjects in samples collected at 2 and 4 min after the drug administration and in some subjects, measurements were also done in samples collected at 7.5, 15, 30, 45, and 60 min. Results: The procedure was reproducible and linear (from 2.5 to 1000 ng/ml). At 2 and 4 min after flumazenil administration, the concentrations did not differ significantly between panicking and nonpanicking subjects, indicating that the pharmacokinetics of the drug is not the major determinant of the responses. There was a steep decline in the plasma concentration-time profile during the first 4 min, reflecting an extensive and rapid distribution after which the decline was slower. Discussion: The method described here is rapid, replicable, and convenient for the determination of flumazenil in plasma. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:57 / 60
页数:4
相关论文
共 19 条
[1]   PHARMACOLOGY OF DORMICUM (MIDAZOLAM) AND ANEXATE (FLUMAZENIL) [J].
AMREIN, R ;
HETZEL, W .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1990, 34 :6-15
[2]   SPEED OF REVERSAL OF MIDAZOLAM-INDUCED RESPIRATORY DEPRESSION BY FLUMAZENIL - A STUDY IN PATIENTS UNDERGOING UPPER GI ENDOSCOPY [J].
CARTER, AS ;
BELL, GD ;
COADY, T ;
LEE, J ;
MORDEN, A .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1990, 34 :59-64
[3]   TOLERANCE OF HEALTHY-VOLUNTEERS TO INTRAVENOUS ADMINISTRATION OF THE BENZODIAZEPINE ANTAGONIST RO-15-1788 [J].
DARRAGH, A ;
LAMBE, R ;
KENNY, M ;
BRICK, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (04) :569-570
[4]  
GELLER E, 1985, ANESTHESIOLOGY, V63, pA157
[5]   THE EFFECTS OF THE BENZODIAZEPINE ANTAGONIST RO 15-1788 ON PSYCHOPHYSIOLOGICAL PERFORMANCE AND SUBJECTIVE MEASURES IN NORMAL SUBJECTS [J].
HIGGITT, A ;
LADER, M ;
FONAGY, P .
PSYCHOPHARMACOLOGY, 1986, 89 (04) :395-403
[6]  
KLOTZ U, 1984, EUR J CLIN PHARMACOL, V27, P115, DOI 10.1007/BF00553165
[7]   FLUNITRAZEPAM AND LORMETAZEPAM DO NOT AFFECT THE PHARMACOKINETICS OF THE BENZODIAZEPINE ANTAGONIST RO-15-1788 [J].
KLOTZ, U ;
DUKA, T ;
DOROW, R ;
DOENICKE, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 19 (01) :95-98
[8]   PHARMACOKINETICS AND CLINICAL USE OF FLUMAZENIL (RO 15-1788) [J].
KLOTZ, U ;
KANTO, J .
CLINICAL PHARMACOKINETICS, 1988, 14 (01) :1-12
[9]  
LAUVEN PM, 1985, ANESTHESIOLOGY, V79, P1183
[10]  
McCloy RF, 1995, ACTA ANAESTH SCAND, V39, P35